Exendin-4 Derivatives with an Albumin-Binding Moiety Show Decreased Renal Retention and Improved GLP-1 Receptor Targeting.
Quick Facts
What This Study Found
Key Numbers
How They Did This
Why This Research Matters
What This Study Doesn't Tell Us
Trust & Context
- Original Title:
- Exendin-4 Derivatives with an Albumin-Binding Moiety Show Decreased Renal Retention and Improved GLP-1 Receptor Targeting.
- Published In:
- Molecular pharmaceutics, 16(9), 3760-3769 (2019)
- Authors:
- Kaeppeli, Simon A M, Jodal, Andreas, Gotthardt, Martin(2), Schibli, Roger, Béhé, Martin
- Database ID:
- RPEP-04269
Evidence Hierarchy
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-04269APA
Kaeppeli, Simon A M; Jodal, Andreas; Gotthardt, Martin; Schibli, Roger; Béhé, Martin. (2019). Exendin-4 Derivatives with an Albumin-Binding Moiety Show Decreased Renal Retention and Improved GLP-1 Receptor Targeting.. Molecular pharmaceutics, 16(9), 3760-3769. https://doi.org/10.1021/acs.molpharmaceut.9b00271
MLA
Kaeppeli, Simon A M, et al. "Exendin-4 Derivatives with an Albumin-Binding Moiety Show Decreased Renal Retention and Improved GLP-1 Receptor Targeting.." Molecular pharmaceutics, 2019. https://doi.org/10.1021/acs.molpharmaceut.9b00271
RethinkPeptides
RethinkPeptides Research Database. "Exendin-4 Derivatives with an Albumin-Binding Moiety Show De..." RPEP-04269. Retrieved from https://rethinkpeptides.com/research/kaeppeli-2019-exendin4-derivatives-with-an
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.